Roberta Anne Gottlieb | |
---|---|
Nationality | American |
Occupation(s) | Oncologist, academic, and researcher |
Known for | Research on mitophagy and mitochondrial biogenesis |
Awards | Women Who Mean Business Award, San Diego Business Journal Fellow, International Society for Heart Research (FISHR) Fellow of the American Heart Association (FAHA) Dorothy and E. Phillip Lyon Endowed Chair in Molecular Cardiology |
Academic background | |
Alma mater | The Johns Hopkins University School of Medicine |
Academic work | |
Institutions | University of California,Los Angeles Cedars-Sinai Medical Center |
Roberta Anne Gottlieb is an American oncologist,academic,and researcher. She is a Professor,and Vice-Chair of Translational Medicine in the Department of Biomedical Sciences at Cedars-Sinai Medical Center,and a Professor of Medicine at the University of California,Los Angeles. [1]
Gottlieb published over 150 papers and has 6 patents awarded. [2] Her research primarily focuses on the molecular basis of myocardial ischemia/reperfusion injury and in developing ways to mitigate damage. She has given over 200 invited talks both at scientific conferences,professional organizations and for the general public. [3]
Gottlieb is a Fellow of the International Society for Heart Research (FISHR), [4] and the American Heart Association (FAHA),and was the Founder and CEO of Radical Therapeutix,from 2005 till 2014,and Co-Founder and Scientific Advisory Board Co-Chair,TissueNetix,from 2011 till 2018.
Gottlieb received her B.A. degree from the Johns Hopkins University in 1980,and her M.D. degree from The Johns Hopkins University School of Medicine in 1984. She completed her Residency in Pediatrics at the University of Texas Health Science Center in 1987,and her Fellowship in Pediatric Hematology &Oncology at the University of Texas M.D. Anderson Cancer Center in 1990. Following this,she became a Postdoctoral Fellow in Michael Karin’s lab at the University of California San Diego School of Medicine until 1992,and at The Scripps Research Institute in the lab of Bernard Babior until 1995. [5]
Gottlieb began her career as a Research Biochemist in the Department of Veterans Affairs Medical Center,San Diego in 1994. During this appointment,she also held concurrent appointments at Scripps Research Institute as an Assistant Member in the Department of Molecular and Experimental Medicine in 1995,and as an Associate Member in 1997 till 1998. In 1997,she was appointed as an Adjunct Assistant Professor in the Department of Medicine University of California San Diego School of Medicine,and from 1999 to 2006,she served at Scripps Research Institute as Associate Professor in the Department of Molecular and Experimental Medicine. Gottlieb was appointed as the Director of San Diego State University BioScience Center from 2007 till 2013. Since 2013,she has been serving as a Research Scientist IV,and a Professor of Cardiology and Biomedical Sciences at Cedars-Sinai Medical Center,and as a Professor of Medicine at the University of California Los Angeles. [1] At Cedars-Sinai Medical Center,she serves as the Director of Metabolism and Mitochondrial Research Core,as Curriculum Director for CSMC Clinical Scholars Program,and as Vice-Chair of Translational Medicine in the Department of Biomedical Sciences. Gottlieb retired from full-time research in March,2022,but remains involved in several ongoing collaborations. [6]
Gottlieb leads ongoing research focused on autophagy, [7] mitophagy and biogenesis,with particular attention to the molecular basis of myocardial ischemia/reperfusion injury and in developing ways to mitigate damage. Her current projects are focused on the development of small-molecular cardioprotective agents for treatment of reperfusion injury,mitochondria and stem cells in anthracycline-induced heart failure,rescue and role of complex I in myocardial ischemic injury,and microbial basis of cardiovascular disease. [8]
In 1994,Gottlieb described the occurrence of programmed cell death (apoptosis) in the ischemic and reperfused heart,and highlighted that programmed cell death taking place during reperfusion is a regulated process that might be blocked to salvage myocardium. [9] Her subsequent work has explored the role of proteases and mitochondrial dysfunction in ischemia/reperfusion injury, [10] and most recently,the importance of autophagy in mitigating reperfusion injury. [11] She has developed tools and techniques in her lab for studying autophagy in cells and in ex vivo and in vivo models. [12]
Gottlieb was the first to suggest that autophagy served a protective role in the setting of myocardial stress. These concepts,tools,and approaches have extended beyond the cardiac field and have led to novel findings in the fields of infectious disease,diabetes,and neurology. [13] Current efforts in her lab are focused on autophagic clearance of mitochondria and mitochondrial biogenesis as essential elements of cardioprotection;efficient removal of damaged mitochondria is important for limiting inflammation mediated by damage associated molecular pattern receptors. [14] [15] In another study,she examined the effect of impaired autophagy on cardioprotection, [16] and the Program Project Grant was focused on the impacts of age and obesity. [17] Her current work is focused on mitophagy and mitochondrial biogenesis as linked processes that are tightly controlled in the heart. In 2018,she with the collaboration of Jennifer Van Eyk,developed polysome profiling and azidohomoalanine labeling to interrogate the newly-synthesized proteome. [18] They also developed advanced proteomic methods to interrogate mitochondria (Mitoplex) [19] and to image mitochondrial turnover (MitoTimer). [20] In 2017,her research identified a new potential way to help cardiac muscle recover from procedures,and revealed that cardiomyocytes can be damaged by the process of stopping and starting the heart during surgeries that use cardiopulmonary bypass machines to take over the heart's functions. [21]
Gottlieb has been at the leading edge of research on mitochondria in cardiac homeostasis,which led her into the study of autophagy and mitophagy including being the first to demonstrate the critical role of Parkin in clearing damaged mitochondria during ischemic stress. [22] Her work,in collaboration with cardiac surgeon Robert M. Mentzer,Jr.,has extended to human studies,further validating the importance of Parkin in human heart. [23]
Gottlieb has worked to determine the role of autophagy and mitophagy in pancreatitis. She initially studied cerulein-induced pancreatitis and now has expanded the focus to pancreatitis induced by ethanol and cigarette smoke. This work is done in collaboration with Honit Piplani and Stephen Pandol. In 2019,she highlighted how simvastatin induces autophagic flux to restore cerulein-impaired phagosome-lysosome fusion in acute pancreatitis,and also discussed the role of simvastatin in enhancing autophagic flux to prevent pancreatic cell injury and pancreatitis. [24] She also contributed to a SEER-Medicare analysis focusing the association of statin use after cancer diagnosis with survival in pancreatic cancer patients,and found out that statin treatment after cancer diagnosis is associated with enhanced survival in patients with low-grade,resectable PDAC. [25]
Autophagy is the natural,conserved degradation of the cell that removes unnecessary or dysfunctional components through a lysosome-dependent regulated mechanism. It allows the orderly degradation and recycling of cellular components. Although initially characterized as a primordial degradation pathway induced to protect against starvation,it has become increasingly clear that autophagy also plays a major role in the homeostasis of non-starved cells. Defects in autophagy have been linked to various human diseases,including neurodegeneration and cancer,and interest in modulating autophagy as a potential treatment for these diseases has grown rapidly.
Reperfusion injury,sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury,is the tissue damage caused when blood supply returns to tissue after a period of ischemia or lack of oxygen. The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than restoration of normal function.
Lipid emulsion or fat emulsion refers to an emulsion of fat for human intravenous use,to administer nutrients to critically-ill patients that cannot consume food. It is often referred to by the brand name of the most commonly used version,Intralipid,which is an emulsion containing soybean oil,egg phospholipids and glycerin,and is available in 10%,20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion,but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
The mitochondrial permeability transition pore is a protein that is formed in the inner membrane of the mitochondria under certain pathological conditions such as traumatic brain injury and stroke. Opening allows increase in the permeability of the mitochondrial membranes to molecules of less than 1500 Daltons in molecular weight. Induction of the permeability transition pore,mitochondrial membrane permeability transition,can lead to mitochondrial swelling and cell death through apoptosis or necrosis depending on the particular biological setting.
An ATP-sensitive potassium channel is a type of potassium channel that is gated by intracellular nucleotides,ATP and ADP. ATP-sensitive potassium channels are composed of Kir6.x-type subunits and sulfonylurea receptor (SUR) subunits,along with additional components. KATP channels are found in the plasma membrane;however some may also be found on subcellular membranes. These latter classes of KATP channels can be classified as being either sarcolemmal ("sarcKATP"),mitochondrial ("mitoKATP"),or nuclear ("nucKATP").
Superoxide dismutase 2,mitochondrial (SOD2),also known as manganese-dependent superoxide dismutase (MnSOD),is an enzyme which in humans is encoded by the SOD2 gene on chromosome 6. A related pseudogene has been identified on chromosome 1. Alternative splicing of this gene results in multiple transcript variants. This gene is a member of the iron/manganese superoxide dismutase family. It encodes a mitochondrial protein that forms a homotetramer and binds one manganese ion per subunit. This protein binds to the superoxide byproducts of oxidative phosphorylation and converts them to hydrogen peroxide and diatomic oxygen. Mutations in this gene have been associated with idiopathic cardiomyopathy (IDC),premature aging,sporadic motor neuron disease,and cancer.
Protein kinase C epsilon type (PKCε) is an enzyme that in humans is encoded by the PRKCE gene. PKCεis an isoform of the large PKC family of protein kinases that play many roles in different tissues. In cardiac muscle cells,PKCεregulates muscle contraction through its actions at sarcomeric proteins,and PKCεmodulates cardiac cell metabolism through its actions at mitochondria. PKCεis clinically significant in that it is a central player in cardioprotection against ischemic injury and in the development of cardiac hypertrophy.
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 is a protein that in humans is encoded by the BNIP3 gene.
Dynamin-1-like protein is a GTPase that regulates mitochondrial fission. In humans,dynamin-1-like protein,which is typically referred to as dynamin-related protein 1 (Drp1),is encoded by the DNM1L gene and is part of the dynamin superfamily (DSP) family of proteins.
Endonuclease G,mitochondrial is an enzyme that in humans is encoded by the ENDOG gene. This protein primarily participates in caspase-independent apoptosis via DNA degradation when translocating from the mitochondrion to nucleus under oxidative stress. As a result,EndoG has been implicated in cancer,aging,and neurodegenerative diseases such as Parkinson’s disease (PD). Regulation of its expression levels thus holds potential to treat or ameliorate those conditions.
Voltage-dependent anion-selective channel protein 2 is a protein that in humans is encoded by the VDAC2 gene on chromosome 10. This protein is a voltage-dependent anion channel and shares high structural homology with the other VDAC isoforms. VDACs are generally involved in the regulation of cell metabolism,mitochondrial apoptosis,and spermatogenesis. Additionally,VDAC2 participates in cardiac contractions and pulmonary circulation,which implicate it in cardiopulmonary diseases. VDAC2 also mediates immune response to infectious bursal disease (IBD).
Voltage-dependent anion-selective channel protein 3 (VDAC3) is a protein that in humans is encoded by the VDAC3 gene on chromosome 8. The protein encoded by this gene is a voltage-dependent anion channel and shares high structural homology with the other VDAC isoforms. Nonetheless,VDAC3 demonstrates limited pore-forming ability and,instead,interacts with other proteins to perform its biological functions,including sperm flagella assembly and centriole assembly. Mutations in VDAC3 have been linked to male infertility,as well as Parkinson’s disease.
Mitophagy is the selective degradation of mitochondria by autophagy. It often occurs to defective mitochondria following damage or stress. The process of mitophagy was first described over a hundred years ago by Margaret Reed Lewis and Warren Harmon Lewis. Ashford and Porter used electron microscopy to observe mitochondrial fragments in liver lysosomes by 1962,and a 1977 report suggested that "mitochondria develop functional alterations which would activate autophagy." The term "mitophagy" was in use by 1998.
Reverse electron flow (also known as reverse electron transport) is a mechanism in microbial metabolism. Chemolithotrophs using an electron donor with a higher redox potential than NAD(P)+/NAD(P)H,such as nitrite or sulfur compounds,must use energy to reduce NAD(P)+. This energy is supplied by consuming proton motive force to drive electrons in a reverse direction through an electron transport chain and is thus the reverse process as forward electron transport. In some cases,the energy consumed in reverse electron transport is five times greater than energy gained from the forward process. Autotrophs can use this process to supply reducing power for inorganic carbon fixation.
Rottlerin (mallotoxin) is a polyphenol natural product isolated from the Asian tree Mallotus philippensis. Rottlerin displays a complex spectrum of pharmacology.
Diallyl trisulfide (DATS),also known as Allitridin,is an organosulfur compound with the formula S(SCH2CH=CH2)2. It is one of several produced by the hydrolysis of allicin,including diallyl disulfide and diallyl tetrasulfide,DATS is one of the most potent.
Nix is a pro-apoptotic gene that is regulated by Histotoxic hypoxia. It expresses a signaling protein related to the BH3-only family. This protein induces autophagy,an intracellular function by which cytoplasmic components are delivered to the lysosome to be broken down and used elsewhere or excreted from the cell. This protein is important in development because it allows cells to have a consistent store of cellular components. It also holds an important role in the differentiation and maturation of erythrocytes and lymphocytes by the process of mitophagy with the help of its regulator BNIP3. Using a gene knockout technique in mice,scientists have been able to attribute this pruning of mitochondria and induction of cellular necrosis to the expression of the Nix gene. The Nix protein may be associated with certain kinds of cancer formation. In mouse models,loss of Nix resulted in a delayed onset of tumors for pancreatic cancer,and was additionally associated with reduced mitophagy and increased oxidative metabolism. Nix therefore may be a tumor promoter for pancreatic cancer.
Cardioprotection includes all mechanisms and means that contribute to the preservation of the heart by reducing or even preventing myocardial damage. Cardioprotection encompasses several regimens that have shown to preserve function and viability of cardiac muscle cell tissue subjected to ischemic insult or reoxygenation. Cardioprotection includes strategies that are implemented before an ischemic event,during an ischemic event and after the event and during reperfusion. These strategies can be further stratified by performing the intervention locally or remotely,creating classes of conditioning known as remote ischemic PC (RIPC),remote ischemic PostC and remost ischemic PerC. Classical (local) preconditioning has an early phase with an immediate onset lasting 2–3 hours that protects against myocardial infarction. The early phase involves post-translational modification of preexisting proteins,brought about by the activation of G protein-coupled receptors as well as downstream MAPK's and PI3/Akt. These signaling events act on the ROS-generating mitochondria,activate PKCεand the Reperfusion Injury Salvage Kinase (RISK) pathway,preventing mitochondrial permeability transition pore (MTP) opening. The late phase with an onset of 12–24 hours that lasts 3–4 days and protects against both infarction and reversible postischemic contractile dysfunction,termed myocardial stunning. This phase involves the synthesis of new cardioprotective proteins stimulated by nitric oxide (NO),ROS and adenosine acting on kinases such as PKCεand Src,which in turn activate gene transcription and upregulation of late PC molecular players.
Perilipin 5,also known as Oxpatperilipin 5 or PLIN5,is a protein that belongs to perilipin family. This protein group has been shown to be responsible for lipid droplet's biogenesis,structure and degradation. In particular,Perilipin 5 is a lipid droplet-associated protein whose function is to keep the balance between lipolysis and lipogenesis,as well as maintaining lipid droplet homeostasis. For example,in oxidative tissues,muscular tissues and cardiac tissues,PLIN5 promotes association between lipid droplets and mitochondria.
Kidney ischemia is a disease with a high morbidity and mortality rate. Blood vessels shrink and undergo apoptosis which results in poor blood flow in the kidneys. More complications happen when failure of the kidney functions result in toxicity in various parts of the body which may cause septic shock,hypovolemia,and a need for surgery. What causes kidney ischemia is not entirely known,but several pathophysiology relating to this disease have been elucidated. Possible causes of kidney ischemia include the activation of IL-17C and hypoxia due to surgery or transplant. Several signs and symptoms include injury to the microvascular endothelium,apoptosis of kidney cells due to overstress in the endoplasmic reticulum,dysfunctions of the mitochondria,autophagy,inflammation of the kidneys,and maladaptive repair.